flow cytometry, in relation to clinical parameters and previously established LN classes assessed according to the ISN/RPS 2003 classification.

Results Lymphocytes percentages in class IV were different from classes III, V or a combination of III and V. In the latter classes, the percentages of the Tregs and Th17 cells were significantly lower, whereas in class IV the increase in FOXP3 in the Tregs and Th17 cells over six months period was significantly higher (Table 1). Changes in glomerular filtration rate and SLEDAI within 5 years did not correlate with single or repeated Tregs measurements.

Conclusions Differences in lymphocyte proportions between class IV and other classes may suggest its distinct pathogenesis and warrants further investigations on their role as LN biomarker.

273 URINARY TWEAK LEVELS AS BIOMARKER OF LUPUS NEPHRITIS IN COLOMBIAN SLE PATIENTS

BL Ortiz Reyes, UT Urrego, AL Vanegas, G Aroca, AC Benavente, CH Muñoz, LA González, ÁG Vásquez, IA Gómez-Puerta*. Universidad de Antioquia, Grupo de Inmunología Celular e Inmunogenética GICYC, Medellín, Colombia; Universidad de Antioquia, Grupo de Reumatología, Medellín, Colombia; Hospital San Vicente Fundación, Reumatología, Medellín, Colombia; Universidad Simon Bolívar, Grupo investigación Nefrología, Barranquilla, Colombia; Universidad Nacional de Colombia, Facultad de Medicina, Bogotá, Colombia

Background and aims TNF-like WEAK inducer of apoptosis (TWEAK), a TNF ligand superfamily is mainly produced by monocytes/macrophages, and is widely expressed at the RNA level in tissues including kidneys. The usefulness of urinary TWEAK (uTWEAK) to identify renal involvement in Mestizo and African-Latin American (ALA) SLE patients has not been examined yet.

Methods Patients meeting the revised ACR criteria for SLE were recruited from 2 different centres at Medellín and Barranquilla, Colombia. uTWEAK were measured using an ELISA kit (R and D system, USA)

Results 158 SLE patients were recruited (89% female) with median age of 32.8±12.1 years and median disease duration of 7.2±6.6 years. Mestizo (77%) and ALA (20%) were majority. 64% of patients had lupus nephritis (LN). 50 out of 71 biopsy proven LN had proliferative forms. Mean SLEDAI score was 8.5±8.7. LN patients (2803±6086 vs 672±1042, p=0.013) (Fig 1A) and ALA patients (3995±9656 vs 1618±2635, p=0.002) had significant higher levels of uTWEAK. uTWEAK levels were higher in patients with active LN and in Class V LN (Fig. 1B). uTWEAK levels were significantly correlated with 24 hours proteiniuria, SLEDAI (Fig. 1C) and serum anti-C1q titers. An ROC curve constructed showed a good level of sensitivity and specificity (Fig. 1D)

Conclusions In our cohort of Colombian SLE patients, uTWEAK levels were 4 and 2 times higher in LN patients and ALA respectively. uTWEAK were significantly higher in active LN and were correlated with disease activity, proteinuria and anti-C1q antibodies.